Omega-3 Fatty Acids, Homocysteine, and the Increased Risk of Cardiovascular Mortality in Major Depressive Disorder

REFERENCES

• Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch Gen Psychiatry 1998;55:580–92.
   PubMed Web of Science ®Google Scholar
• Barefoot JC, Schroll M. Symptoms of depression, acute myo- cardial infarction, and total mortality in a community sample. Circulation 1996;93:1976–80.
   PubMed Web of Science ®Google Scholar
• Pratt LA, Ford DE, Crum RM, Armenian HK, Gallo JJ, Ea- ton WW. Depression, psychotropic medication, and risk of myocardial infarction: prospective data from the Baltimore ECA follow-up. Circulation 1996;94:3123–9.
   Google Scholar
• Ford DE, Mead LA, Chang PP, Cooper-Patrick L, Wang NY, Klag MJ. Depression is a risk factor for coronary artery dis- ease in men: the Precursors Study. Arch Intern Med 1998; 158:1422–6.
   PubMed Web of Science ®Google Scholar
• Carney RM, Rich MW, Freedland KE, Saini J, Te Velde A, Simeone C, et al. Major depressive disorder predicts cardiac events in patients with coronary artery disease. Psychosom Med 1988;50:627–33.
   PubMed Web of Science ®Google Scholar
• Frasure-Smith N, Lespe´rance F, Talajic M. Depression and 18-month prognosis after myocardial infarction. Circulation 1995;91:999–1005.
   PubMed Web of Science ®Google Scholar
• Barefoot JC, Helms MJ, Mark DB, Blumenthal JA, Califf RM, Haney TL, et al. Depression and long-term mortality risk in patients with coronary artery disease. Am J Cardiol 1996;78:613–7.
   PubMed Web of Science ®Google Scholar
• Frasure-Smith N, Lespe´rance F, Juneau M, Talajic M, Bour- assa MG. Gender, depression, and one-year prognosis after myocardial infarction. Psychosom Med 1999;61:26–37.
   Google Scholar
• Ahern DK, Gorkin L, Anderson JL, Tierney C, Hallstrom A, Ewart C, et al. Biobehavioral variables and mortality or car- diac arrest in the Cardiac Arrhythmia Pilot Study (CAPS). Am J Cardiol 1990;66:59–62.
   PubMed Web of Science ®Google Scholar
• Ladwig KH, Kieser M, Ko¨nig J, Breithardt G, Borggrefe M. Affective disorders and survival after acute myocardial in- farction: results from the Post-infarction Late Potential Study. Eur Heart J 1991;12:959–64.
   PubMed Web of Science ®Google Scholar
• Carney RM, Freedland KE, Rich MW, Smith LJ, Jaffe AS. Ventricular tachycardia and psychiatric depression in pa- tients with coronary artery disease. Am J Med 1993;95:23–8.
   PubMed Web of Science ®Google Scholar
• Carney RM, Saunders RD, Freedland KE, Stein P, Rich MW, Jaffe AS. Association of depression with reduced heart rate variability in coronary artery disease. Am J Cardiol 1995; 76:562–4.
   PubMed Web of Science ®Google Scholar
• Dunbar SB, Kimble LP, Jenkins LS, Hawthorne M, Dudley W, Slemmons M, et al. Association of mood disturbance and arrhythmia events in patients after cardioverter defibrillator implantation. Depress Anxiety 1999;9:163–8.
   PubMedGoogle Scholar
• Yeragani VK. Major depression and long-term heart period variability. Depress Anxiety 2000;12:51–2.
   Google Scholar
• Krishnan KR. Depression as a contributing factor in cerebro- vascular disease. Am Heart J 2000;140:70–6.
   Google Scholar
• Jonas BS, Mussolino ME. Symptoms of depression as a prospective risk factor for stroke. Psychosom Med 2000; 62:463–71.
   PubMed Web of Science ®Google Scholar
• Stewart TD, Atlas SA. Syndrome X, depression, and chaos: relevance to medical practice. Conn Med 2000;64:343–5.
   Google Scholar
• Reaven GM. Banting Lecture 1988: role of insulin resistance in human disease. Diabetes 1988;37:1595–607.
   Google Scholar
• Lustman PJ, Freedland KE, Griffith LS, Clouse RE. Fluoxe- tine for depression in diabetes: a randomized double-blind placebo-controlled trial. Diabetes Care 2000;23:618–23.
   PubMed Web of Science ®Google Scholar
• Maheux P, Ducros F, Bourque J, Garon J, Chiasson JL. Flu- oxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss. Int J Obes Relat Metab Disord 1997;21:97–102.
   PubMed Web of Science ®Google Scholar
• Lustman PJ, Griffith LS, Clouse RE, Freedland KE, Eisen SA, Rubin EH, et al. Effects of nortriptyline on depression and glycemic control in diabetes: results of a double-blind, placebo-controlled trial. Psychosom Med 1997;59:241–50.
   PubMed Web of Science ®Google Scholar
• Thakore JH, Richards PJ, Reznek RH, Martin A, Dinan TG. Increased intra-abdominal fat deposition in patients with major depressive illness as measured by computed tomogra- phy. Biol Psychiatry 1997;41:1140–2.
   Google Scholar
• Despre´s JP. Abdominal obesity as important component of insulin-resistance syndrome. Nutrition 1993;9:452–9.
   PubMed Web of Science ®Google Scholar
• Visser M, Seidell JC, Koppeschaar HP, Smits P. The effect of fluoxetine on body weight, body composition and visceral fat accumulation. Int J Obes Relat Metab Disord 1993;17:247–53.
   Google Scholar
• Shapiro PA, Lespe´rance F, Frasure-Smith N, O’Connor CM, Baker B, Jiang JW, et al. An open-label preliminary trial of sertraline for treatment of major depression after acute myo- cardial infarction (the SADHAT Trial). Am Heart J 1999; 137:1100–6.
   PubMed Web of Science ®Google Scholar
• Blumenthal JA, O’Connor C, Hinderliter A, Fath K, Hegde SB, Miller G, et al. Psychosocial factors and coronary disease: a national multicenter clinical trial (ENRICHD) with a North Carolina focus. NC Med J 1997;58:440–4.
   Google Scholar
• Anonymous. Enhancing recovery in coronary heart disease patients (ENRICHD): study design and methods. Am Heart J 2000;139:1–9.
   Google Scholar
• Coryell W, Turvey C, Leon A, Maser JD, Solomon D, Endicott J, et al. Persistence of depressive symptoms and cardiovascu- lar death among patients with affective disorder. Psychosom Med 1999;61:755–61.
   Google Scholar
• Siscovick DS, Raghunathan TE, King I, Weinmann S, Wicklund KG, Albright J, et al. Dietary intake and cell mem- brane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. JAMA 1995;274:1363–7.
   PubMed Web of Science ®Google Scholar
• Adams PB, Lawson S, Sanigorski A, Sinclair AJ. Arachidonic acid to eicosapentaenoic acid ratio in blood correlates positively with clinical symptoms of depression. Lipids 1996; 31(suppl):S157–61.
   Google Scholar
• Edwards R, Peet M, Shay J, Horrobin D. Omega-3 polyun- saturated fatty acid levels in the diet and in red blood cell membranes of depressed patients. J Affect Disord 1998;48:149–55.
   PubMed Web of Science ®Google Scholar
• Peet M, Murphy B, Shay J, Horrobin D. Depletion of omega- 3 fatty acid levels in red blood cell membranes of depressive patients. Biol Psychiatry 1998;43:315–9.
   PubMed Web of Science ®Google Scholar
• Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of ho- mocysteinemia in an elderly population. JAMA 1993;270:2693–8.
   PubMed Web of Science ®Google Scholar
• Selhub J. Homocysteine metabolism. Annu Rev Nutr 1999; 19:217–46.
   PubMed Web of Science ®Google Scholar
• Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing fo- lic acid intakes. JAMA 1995;274:1049–57.
   PubMed Web of Science ®Google Scholar
• Bottiglieri T, Laundy M, Crellin R, Toone BK, Carney MW, Reynolds EH. Homocysteine, folate, methylation, and mono- amine metabolism in depression. J Neurol Neurosurg Psy- chiatry 2000;69:228–32.
   PubMed Web of Science ®Google Scholar
• Coppen A, Bailey J. Enhancement of the antidepressant ac- tion of fluoxetine by folic acid: a randomised, placebo con- trolled trial. J Affect Disord 2000;60:121–30.
   PubMed Web of Science ®Google Scholar
• Fava M, Borus JS, Alpert JE, Nierenberg AA, Rosenbaum JF, Bottiglieri T. Folate, vitamin B12, and homocysteine in major depressive disorder. Am J Psychiatry 1997;154:426–8.
   PubMed Web of Science ®Google Scholar
• Maes M, Christophe A, Delanghe J, Altamura C, Neels H, Meltzer HY. Lowered w3 polyunsaturated fatty acids in se- rum phospholipids and cholesteryl esters of depressed pa- tients. Psychiatry Res 1999;85:275–91.
   PubMed Web of Science ®Google Scholar
• Krauss RM, Eckel RH, Howard B, Appel LJ, Daniels SR, Deckelbaum RJ, et al. AHA dietary guidelines: revision 2000: a statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Circulation 2000;102:2284–99.
   PubMed Web of Science ®Google Scholar
• Singh RB, Niaz MA, Sharma JP, Kumar R, Rastogi V, Mosh- iri M. Randomized, double-blind, placebo-controlled trial of fish oil and mustard oil in patients with suspected acute myocardial infarction: the Indian experiment of infarct survival-4. Cardiovasc Drugs Ther 1997;11:485–91.
   Google Scholar
• Burr ML, Fehily AM, Gilbert JF, Rogers S, Holliday RM, Sweetnam PM, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and re- infarction trial (DART). Lancet 1989;2:757–61.
   PubMed Web of Science ®Google Scholar
• De Lorgeril M, Renaud S, Mamelle N, Salen P, Martin JL, Monjaud I, et al. Mediterranean alpha-linolenic acid–rich diet in secondary prevention of coronary heart disease. Lan- cet 1994;343:1454–9.
   PubMed Web of Science ®Google Scholar
• De Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial in- farction: final report of the Lyon Diet Heart Study. Circula- tion 1999;99:779–85.
   Google Scholar
• Anonymous. Dietary supplementation with n-3 polyunsatu- rated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999;354:447–55.
   Google Scholar
• Albert CM, Hennekens CH, O’Donnell CJ, Ajani UA, Carey VJ, Willett WC, et al. Fish consumption and risk of sudden cardiac death. JAMA 1998;279:23–8.
   PubMed Web of Science ®Google Scholar
• Billman GE, Kang JX, Leaf A. Prevention of sudden cardiac death by dietary pure omega-3 polyunsaturated fatty acids in dogs. Circulation 1999;99:2452–7.
   PubMed Web of Science ®Google Scholar
• Ellis FR, Sanders TA. Long chain polyunsaturated fatty acids in endogenous depression. J Neurol Neurosurg Psychi- atry 1977;40:168–9.
   PubMed Web of Science ®Google Scholar
• Kaiya H, Horrobin DF, Manku MS, Fisher NM. Essential and other fatty acids in plasma in schizophrenics and normal individuals from Japan. Biol Psychiatry 1991;30:357–62.
   PubMedGoogle Scholar
• Stoll AL, Severus WE, Freeman MP, Rueter S, Zboyan HA, Diamond E, et al. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry 1999;56:407–12.
   PubMed Web of Science ®Google Scholar
• Bjerve KS, Fischer S, Wammer F, Egeland T. Alpha-linolenic acid and long-chain omega-3 fatty acid supplementation in three patients with omega-3 fatty acid deficiency: effect on lymphocyte function, plasma and red cell lipids, and prostan- oid formation. Am J Clin Nutr 1989;49:290–300.
   PubMed Web of Science ®Google Scholar
• Puri BK, Richardson AJ, Horrobin DF, Easton T, Saeed N, Oatridge A, et al. Eicosapentaenoic acid treatment in schizo- phrenia associated with symptom remission, normalisation of blood fatty acids, reduced neuronal membrane phospho- lipid turnover and structural brain changes. Int J Clin Pract 2000;54:57–63.
   PubMed Web of Science ®Google Scholar
• Heinecke JW. Is lipid peroxidation relevant to atherogenesis? [Letter]. J Clin Invest 1999;104:135–6.
   PubMed Web of Science ®Google Scholar
• De la Fuente M, Ferra´ ndez MD, Burgos MS, Soler A, Prieto A, Miquel J. Immune function in aged women is improved by ingestion of vitamins C and E. Can J Physiol Pharmacol 1998;76:373–80.
   Google Scholar
• Rudin DO. The major psychoses and neuroses as omega-3 essential fatty acid deficiency syndrome: substrate pellagra. Biol Psychiatry 1981;16:837–50.
   PubMedGoogle Scholar
• Hibbeln JR, Umhau JC, George DT, Salem N Jr. Do plasma polyunsaturates predict hostility and depression? World Rev Nutr Diet 1997;82:175–86.
   PubMed Web of Science ®Google Scholar
• Hibbeln JR. Fish consumption and major depression [Let- ter]. Lancet 1998;351:1213.
   PubMed Web of Science ®Google Scholar
• Bates CE. Racially determined abnormal essential fatty acid and prostaglandin metabolism and food allergies linked to autoimmune, inflammatory, and psychiatric disorders among coastal British Columbia Indians. Med Hypotheses 1988; 25:103–9.
   Google Scholar
• Wald NJ, Watt HC, Law MR, Weir DG, McPartlin J, Scott JM. Homocysteine and ischemic heart disease: results of a prospective study with implications regarding prevention. Arch Intern Med 1998;158:862–7.
   PubMed Web of Science ®Google Scholar
• Hankey GJ, Eikelboom JW. Homocysteine and vascular dis- ease. Lancet 1999;354:407–13.
   PubMed Web of Science ®Google Scholar
• Stubbs PJ, Al-Obaidi MK, Conroy RM, Collinson PO, Gra- ham IM, Noble MIM. Effect of plasma homocysteine concen- tration on early and late events in patients with acute coro- nary syndromes. Circulation 2000;102:605–10.
   Google Scholar
• Peterson JC, Spence JD. Vitamins and progression of athero- sclerosis in hyper-homocyst(e)inaemia [Letter]. Lancet 1998;351:263.
   PubMed Web of Science ®Google Scholar
• Hackam DG, Peterson JC, Spence JD. What level of plasma homocyst(e)ine should be treated? Effects of vitamin therapy on progression of carotid atherosclerosis in patients with ho- mocyst(e)ine levels above and below 14 µmol/L. Am J Hyper- tens 2000;13:105–10.
   PubMed Web of Science ®Google Scholar
• De Jong SC, Stehouwer CD, Van den Berg M, Geurts TW, Bouter LM, Rauwerda JA. Normohomocysteinaemia and vitamin-treated hyperhomocysteinaemia are associated with similar risks of cardiovascular events in patients with pre- mature peripheral arterial occlusive disease: a prospective cohort study. J Intern Med 1999;246:87–96.
   Google Scholar
• Vermeulen EG, Stehouwer CD, Twisk JW, Van den Berg M, De Jong SC, Mackaay AJ, et al. Effect of homocysteine- lowering treatment with folic acid plus vitamin B6 on pro- gression of subclinical atherosclerosis: a randomised, placebo-controlled trial. Lancet 2000;355:517–22.
   PubMed Web of Science ®Google Scholar
• Bostom AG, Jacques PF, Nadeau MR, Williams RR, Ellison RC, Selhub J. Post-methionine load hyperhomocysteinemia in persons with normal fasting total plasma homocysteine: initial results from the NHLBI Family Heart Study. Athero- sclerosis 1995;116:147–51.
   Google Scholar
• Folsom AR, Nieto FJ, McGovern PG, Tsai MY, Malinow MR, Eckfeldt JH, et al. Prospective study of coronary heart dis- ease incidence in relation to fasting total homocysteine, re- lated genetic polymorphisms, and B vitamins: the Athero- sclerosis Risk in Communities (ARIC) study. Circulation 1998;98:204–10.
   PubMedGoogle Scholar
• Robinson K, Arheart K, Refsum H, Brattstro¨m L, Boers G, Ueland P, et al. Low circulating folate and vitamin B6 concen- trations: risk factors for stroke, peripheral vascular disease, and coronary artery disease. Circulation 1998;97:437–43.
   PubMed Web of Science ®Google Scholar
• Rimm EB, Willett WC, Hu FB, Sampson L, Colditz GA, Man- son JE, et al. Folate and vitamin B6 from diet and supple- ments in relation to risk of coronary heart disease among women. JAMA 1998;279:359–64.
   Google Scholar
• Malinow MR, Ducimetiere P, Luc G, Evans AE, Arveiler D, Cambien F, et al. Plasma homocyst(e)ine levels and graded risk for myocardial infarction: findings in two populations at contrasting risk for coronary heart disease. Atherosclerosis 1996;126:27–34.
   Google Scholar
• Graham IM, Daly LE, Refsum HM, Robinson K, Brattstro¨m LE, Ueland PM, et al. Plasma homocysteine as a risk factor for vascular disease. JAMA 1997;277:1775–81.
   PubMed Web of Science ®Google Scholar
• Nyga° rd O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337:230–6.
   Google Scholar
• Omenn GS, Beresford SA, Motulsky AG. Preventing coro- nary artery disease: B vitamins and homocysteine [Letter]. Circulation 1998;97:421–4.
   PubMedGoogle Scholar
• Van der Griend R, Haas FJ, Biesma DH, Duran M, Meuwis- sen OJ, Banga JD. Combination of low-dose folic acid and pyridoxine for treatment of hyperhomocysteinaemia in pa- tients with premature arterial disease and their relatives. Atherosclerosis 1999;143:177–83.
   Google Scholar
• Echols JC, Naidoo U, Salzman C. SAMe (S-adenosylmethio- nine). Harvard Rev Psychiatry 2000;8:84–90.
   PubMed Web of Science ®Google Scholar
• Kagan BL, Sultzer DL, Rosenlicht N, Gerner RH. Oral S- adenosylmethionine in depression: a randomized, double- blind, placebo-controlled trial. Am J Psychiatry 1990;147:591–5.
   PubMed Web of Science ®Google Scholar
• Loehrer FM, Schwab R, Angst CP, Haefeli WE, Fowler B. Influence of oral S-adenosylmethionine on plasma 5- methyltetrahydrofolate, S-adenosylhomocysteine, homocys- teine and methionine in healthy humans. J Pharmacol Exp Ther 1997;282:845–50.
   PubMedGoogle Scholar
• Guaraldi GP, Fava M, Mazzi F, La Greca P. An open trial of methyltetrahydrofolate in elderly depressed patients. Ann Clin Psychiatry 1993;5:101–5.
   PubMedGoogle Scholar
• Durand P, Prost M, Blache D. Pro-thrombotic effects of a folic acid deficient diet in rat platelets and macrophages related to elevated homocysteine and decreased n-3 polyunsaturated fatty acids. Atherosclerosis 1996;121:231–43.
   PubMed Web of Science ®Google Scholar
• Pita ML, Delgado MJ. Folate administration increases n-3 polyunsaturated fatty acids in rat plasma and tissue lipids. Thromb Haemost 2000;84:420–3.
   Google Scholar
• Maes M, De Vos N, Pioli R, Demedts P, Wauters A, Neels H, et al. Lower serum vitamin E concentrations in major de- pression: another marker of lowered antioxidant defenses in that illness. J Affect Disord 2000;58:241–6.
   PubMed Web of Science ®Google Scholar
• Musselman DL, Tomer A, Manatunga AK, Knight BT, Porter MR, Kasey S, et al. Exaggerated platelet reactivity in major depression. Am J Psychiatry 1996;153:1313–7.
   PubMed Web of Science ®Google Scholar
• Markovitz JH, Shuster JL, Chitwood WS, May RS, Tolbert LC. Platelet activation in depression and effects of sertraline treatment: an open-label study. Am J Psychiatry 2000;157:1006–8.
   PubMed Web of Science ®Google Scholar
• Musselman DL, Marzec UM, Manatunga A, Penna S, Reem- snyder A, Knight BT, et al. Platelet reactivity in depressed patients treated with paroxetine: preliminary findings. Arch Gen Psychiatry 2000;57:875–82.
   Google Scholar
• Timar O, Sestier F, Levy E. Metabolic syndrome X: a review. Can J Cardiol 2000;16:779–89.
   PubMed Web of Science ®Google Scholar
• Anfossi G, Mularoni EM, Burzacca S, Ponziani MC, Mas- succo P, Mattiello L, et al. Platelet resistance to nitrates in obesity and obese NIDDM, and normal platelet sensitivity to both insulin and nitrates in lean NIDDM. Diabetes Care 1998;21:121–6.
   Google Scholar
• Islim IF, Bareford D, Ebanks M, Beevers DG. The role of platelets in essential hypertension. Blood Press 1995;4:199–214.
   PubMedGoogle Scholar
• Panzarino PJ Jr. The costs of depression: direct and indirect; treatment versus nontreatment. J Clin Psychiatry 1998; 59(suppl 20):11–4.
   Google Scholar
• Prasad K. Dietary flax seed in prevention of hypercholester- olemic atherosclerosis. Atherosclerosis 1997;132:69–76.
   Google Scholar
• Vanharanta M, Voutilainen S, Lakka TA, Van der Lee M, Ad- lercreutz H, Salonen JT. Risk of acute coronary events ac- cording to serum concentrations of enterolactone: a prospec- tive population-based case-control study. Lancet 1999;354:2112–5.
   Google Scholar
• Hutchins AM, Martini MC, Olson BA, Thomas W, Slavin JL. Flaxseed influences urinary lignan excretion in a dose- dependent manner in postmenopausal women. Cancer Epi- demiol Biomarkers Prev 2000;9:1113–8.
   PubMed Web of Science ®Google Scholar
• Malinow MR, Bostom AG, Krauss RM. Homocyst(e)ine, diet, and cardiovascular diseases: a statement for healthcare pro- fessionals from the Nutrition Committee, American Heart Association. Circulation 1999;99:178–82.
   PubMed Web of Science ®Google Scholar
• Nedrebø BG, Ericsson UB, Nyga° rd O, Refsum H, Ueland PM, Aakvaag A, et al. Plasma total homocysteine levels in hyperthyroid and hypothyroid patients. Metabolism 1998; 47:89–93.
   Google Scholar
• Hussein WI, Green R, Jacobson DW, Faiman C. Normaliza- tion of hyperhomocysteinemia with L-thyroxine in hypothy- roidism. Ann Intern Med 1999;131:348–51.
   PubMed Web of Science ®Google Scholar
• Catargi B, Parrot-Roulaud F, Cochet C, Ducassou D, Roger P, Tabarin A. Homocysteine, hypothyroidism, and effect of thyroid hormone replacement. Thyroid 1999;9:1163–6.
   PubMed Web of Science ®Google Scholar
• Selhub J, Bagley LC, Miller J, Rosenberg IH. B vitamins, homocysteine, and neurocognitive function in the elderly. Am J Clin Nutr 2000;71(suppl):614–20S.
   Google Scholar
• Cravo ML, Glo´ria LM, Selhub J, Nadeau MR, Camilo ME, Resende MP, et al. Hyperhomocysteinemia in chronic alco- holism: correlation with folate, vitamin B-12, and vitamin B- 6 status. Am J Clin Nutr 1996;63:220–4.
   PubMed Web of Science ®Google Scholar
• Yates AA, Schlicker SA, Suitor CW. Dietary reference in- takes: the new basis for recommendations for calcium and related nutrients, B vitamins, and choline. J Am Diet Assoc 1998;98:699–706.
   PubMed Web of Science ®Google Scholar
• Elia M. Oral or parenteral therapy for B12 deficiency. Lancet 1998;352:1721–2.
   PubMedGoogle Scholar
• Stahl SM. Does evidence from clinical trials in psychophar- macology apply in clinical practice? J Clin Psychiatry 2001; 62:6–7.
   PubMed Web of Science ®Google Scholar
• Menger MD, Vollmar B. Non-publication and negative stud- ies: their significance for opinion formation and research [In German with an English abstract]. Dtsch Med Wochenschr 2000;125:1129–30.
   Google Scholar